Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. Senior Vice President, Finance Agarwal Arjun reported open-market sales of common stock and exercises of employee stock options on July 13, 2026. He sold a total of 9,999 shares of common stock in multiple open-market transactions at weighted-average prices between $82.49 and $85.69 per share, pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. On the same date, he exercised employee stock options to acquire 9,999 shares of common stock at exercise prices of $34.39 and $12.50 per share.
ORKA has a notice of proposed sale under Form 144 for 28,588 common shares, to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares are planned to be sold on July 13, 2026 in connection with an exercise of stock options for cash.
The filing also lists recent Rule 10b5-1 sales by Arjun Agarwal over the prior three months, including multiple transactions in May and June 2026 involving several thousand shares each.
ORKA notice of proposed sale: 3,553,410 shares of Common Stock are tied to the conversion of Series B Non-Voting Convertible Preferred Stock, dated 07/01/2026. The filing lists Goldman Sachs & Co. LLC as the broker/dealer associated with the transaction.
Oruka Therapeutics, Inc. received an updated Schedule 13D/A from Fairmount-affiliated investors detailing their ownership and recent transactions in the company’s common stock. The reporting group discloses beneficial ownership of securities representing about 19.5% of Oruka’s common stock, based on 74,733,166 shares outstanding as of July 1, 2026.
The holdings include common shares, options, Pre-Funded Warrants and Series B non-voting convertible preferred stock that can convert into additional common shares, all subject to stated beneficial ownership limitations of 9.99% and 19.99%. On July 1, 2026, Fairmount Healthcare Fund II L.P. converted 42,641 Series B preferred shares into 3,553,410 common shares for no cash consideration and sold those shares in a block trade at $84.43 per share.
Fairmount Healthcare Fund II L.P., an entity managed by Fairmount Funds Management LLC, converted 42,641 shares of Series B Preferred Stock of Oruka Therapeutics, Inc. into 3,553,410 shares of Common Stock on July 1, 2026 for no cash consideration, in line with the Series B terms.
On the same date, Fairmount Healthcare Fund II L.P. sold 3,553,410 Common shares at $84.43 per share, and reported 1,131,954 Common shares held indirectly afterward, along with 94,497 Series B Preferred shares remaining outstanding. A related vehicle, Fairmount Healthcare Co-Invest III L.P., reported indirect holdings of 2,573,308 Common shares. Fairmount Funds Management LLC and its managers Peter Harwin and Tomas Kiselak disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported a set of routine equity transactions. She sold a total of 5,000 shares of common stock in open-market trades at weighted average prices in the mid‑$90s per share, executed under a Rule 10b5‑1 trading plan entered into on September 19, 2025.
On the same date, she exercised an employee warrant to acquire 5,000 shares of common stock at an exercise price of $7.80 per share, fully converting this derivative position. Following these transactions, she directly holds 236,384 shares of Oruka Therapeutics common stock.
Oruka Therapeutics, Inc. Senior Vice President of Finance Arjun Agarwal reported selling 1,587 shares of Common Stock in open-market transactions. The sales occurred at prices of about $82.15 and $80.01 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan entered into on February 11, 2026.
Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported a mix of option exercises and related share sales in company common stock. On June 12, 2026, he exercised employee stock options for 8,000 shares at $12.50 per share and 1,459 shares at $34.39 per share, increasing his direct holdings.
On the same day and on June 15, 2026, he sold an aggregate of 9,854 shares of common stock in multiple open-market transactions at weighted average prices ranging from about the high $60s to around $70 per share. According to the footnotes, these sales were carried out under Oruka’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations tied to vesting of restricted stock units and were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
Following these transactions, Agarwal directly holds 16,899 shares of Oruka Therapeutics common stock. The filing also notes that his holdings include 888 shares acquired through the company’s stock purchase plan on June 8, 2026.
Oruka Therapeutics Chief Medical Officer Joana Goncalves reported option-related trades and share sales in Oruka Therapeutics, Inc. common stock. On June 15, 2026, she exercised options and warrants to acquire 7,000 shares at exercise prices of $7.80 and $6.84 per share, and sold 7,947 shares in multiple open-market transactions at weighted-average prices around $68–$71 per share.
Following these transactions, she directly held 32,718 shares of common stock. According to the footnotes, some sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on September 19, 2025, and other sales were automatic sell-to-cover transactions to satisfy tax withholding obligations from vesting restricted stock units, indicating a largely routine, pre-planned liquidity and tax-management pattern.
Oruka Therapeutics, Inc.'s Chief Executive Officer Lawrence Otto Klein reported an automatic sale of 1,729 shares of common stock at $69.69 per share. According to the footnote, this was carried out under the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations from vesting restricted stock units.
After this tax-related sale, Klein directly holds 925,580 shares of Oruka Therapeutics common stock. Because the transaction was solely to cover taxes and was not discretionary, it functions more like a routine payroll event than an active decision to reduce his investment.